Economy · Weltweit · Original source dated 2026-10-30 ·
AstraZeneca's profit rises 23% on cancer drugs and unveils cost-saving plan
AstraZeneca reported a 23% net profit increase in Q3 on strong cancer drug sales, alongside a $1.5 billion savings program.
In its third-quarter report, AstraZeneca announced a 23% increase in net profit year-over-year, largely driven by booming sales of its cancer drugs. The British pharmaceutical firm also revealed a significant cost-saving plan aimed at saving $1.5 billion annually to reinvest in the development of new medicines. This initiative is expected to improve resource allocation and expedite product development.
Sources and context
Source: Euronews Welt
Original source ↗